Comparing CVD events based on severity of hemophilia and treatment type
| CVD event . | Complete cohort (N = 687) . | P . | QRISK available (n = 579) . | P . |
|---|---|---|---|---|
| Severe, treated OD | 2.2% (3/135) | Ref | 0% (0/122) | Ref |
| Severe, treated on prophylaxis | 3.9% (8/206) | .303 | 2.2% (4/182) | .127 |
| All patients, except those with severe hemophilia treated OD | 3.3% (18/552) | .383 | 2.0% (9/457) | .117 |
| CVD event . | Complete cohort (N = 687) . | P . | QRISK available (n = 579) . | P . |
|---|---|---|---|---|
| Severe, treated OD | 2.2% (3/135) | Ref | 0% (0/122) | Ref |
| Severe, treated on prophylaxis | 3.9% (8/206) | .303 | 2.2% (4/182) | .127 |
| All patients, except those with severe hemophilia treated OD | 3.3% (18/552) | .383 | 2.0% (9/457) | .117 |
No significant difference in CVD events was found between patients with severe hemophilia treated with on-demand (OD) therapy vs those on prophylaxis and vs all other patients (all patients except those with severe hemophilia treated with OD therapy). Analysis was done in in the complete cohort and exclusively in those with a QRISK score.